



**ASX & MEDIA RELEASE  
23 NOVEMBER, 2010**

**GLYCOTEX, INC., AWARDED CASH GRANT UNDER THE US GOVERNMENT QUALIFYING THERAPEUTIC DISCOVERY PROGRAM**

Novogen Limited's subsidiary, Glycotex, Inc., has made the following announcement:

Rockville, Maryland USA, 23 November, 2010 – Glycotex, Inc., a clinical stage biopharmaceutical company, announced today that it has been awarded a cash grant totaling US\$244,479 under the US Government's Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

Glycotex received the grant for its program to develop GLYC-101 Gel investigational product for the treatment of acute and chronic wounds.

**About GLYC-101**

GLYC-101 is being developed to stimulate and modulate the natural cascade of wound healing activities of several cell populations. The product candidate is a topical gel to be applied directly on the wound surface.

The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers, and diabetic ulcers.

**About Glycotex, Inc.**

Glycotex, Inc. is a US based development stage biopharmaceutical company focused on discovering and developing therapies intended to accelerate human wound healing and tissue repair across a wide range of human applications. It has licensed from Novogen Limited (ASX: NRT NASDAQ: NVGN) certain patent rights and know-how to use and exploit its technology in a wide range of wound healing applications. Glycotex, Inc., is an 81 percent owned subsidiary of Novogen Limited. For more information, visit [www.glycotexinc.com](http://www.glycotexinc.com).

*Under US law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the*

*patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.*

---

|                              |   |                                                                                                                         |
|------------------------------|---|-------------------------------------------------------------------------------------------------------------------------|
| ISSUED FOR                   | : | NOVOGEN LIMITED                                                                                                         |
| LISTINGS                     | : | ASX (CODE NRT), NASDAQ (CODE NVGN).                                                                                     |
| FOR FURTHER<br>INFORMATION : | : | RHONDA CHIGER, RX COMMUNICATIONS GROUP, LLC -<br>+1 917 322-2569 <a href="mailto:rchiger@rxir.com">rchiger@rxir.com</a> |
| ISSUED BY                    | : | WESTBROOK COMMUNICATIONS                                                                                                |
| CONTACT                      | : | IAN WESTBROOK TEL (02) 9231 0922                                                                                        |